Persistent Asset Partners Ltd Makes New $796,000 Investment in Tenax Therapeutics, Inc. $TENX

Persistent Asset Partners Ltd acquired a new position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 65,272 shares of the specialty pharmaceutical company’s stock, valued at approximately $796,000. Persistent Asset Partners Ltd owned 1.05% of Tenax Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in TENX. Marshall Wace LLP raised its stake in Tenax Therapeutics by 68.2% in the 4th quarter. Marshall Wace LLP now owns 298,153 shares of the specialty pharmaceutical company’s stock worth $3,634,000 after acquiring an additional 120,944 shares during the last quarter. Siren L.L.C. grew its stake in Tenax Therapeutics by 21.2% during the 4th quarter. Siren L.L.C. now owns 427,141 shares of the specialty pharmaceutical company’s stock valued at $5,207,000 after purchasing an additional 74,700 shares during the last quarter. Renaissance Technologies LLC grew its stake in Tenax Therapeutics by 121.9% during the 4th quarter. Renaissance Technologies LLC now owns 125,579 shares of the specialty pharmaceutical company’s stock valued at $1,531,000 after purchasing an additional 68,979 shares during the last quarter. Letko Brosseau & Associates Inc. acquired a new position in shares of Tenax Therapeutics in the fourth quarter valued at about $130,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Tenax Therapeutics in the fourth quarter valued at about $273,000. 1.67% of the stock is owned by hedge funds and other institutional investors.

Tenax Therapeutics Stock Down 1.9%

Shares of TENX opened at $11.33 on Wednesday. The company has a market capitalization of $300.47 million, a price-to-earnings ratio of -8.09 and a beta of 0.98. Tenax Therapeutics, Inc. has a 52 week low of $5.34 and a 52 week high of $18.38. The stock’s 50-day moving average price is $12.60 and its 200-day moving average price is $12.79.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Tuesday, May 12th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.05. As a group, equities analysts anticipate that Tenax Therapeutics, Inc. will post -1.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a report on Tuesday, March 10th. Guggenheim increased their price target on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Piper Sandler raised their price target on shares of Tenax Therapeutics from $20.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, June 12th. Cantor Fitzgerald assumed coverage on shares of Tenax Therapeutics in a research note on Tuesday, March 17th. They set an “overweight” rating and a $35.00 price objective for the company. Finally, Lifesci Capital raised shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.67.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.